Literature DB >> 2765095

Chronic experimental autoimmune encephalomyelitis in the guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease.

R Lebar1, M Baudrimont, C Vincent.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) can be transferred adoptively with T cells sensitized to the basic protein of myelin (BP). However, in the guinea pig, the chronic form of EAE has not been found to be inducible with BP alone, nor has it been adoptively transferred. An antibody response to the central nervous system (CNS) myelin autoantigens was looked for in serum and target CNS tissue in S13 guinea pigs with isologous CNS tissue-induced chronic EAE. Antibody activity was estimated by an immunoenzymatic technique and by autoradiography, using immunoprecipitated and electrophoresed relevant radiolabelled antigens. In serum, IgG antibody response to BP and M2 reached its maximum level 30 to 40 d after immunization and then declined progressively until it became undetectable. On the other hand, while anti-BP antibodies were seldom detected in CNS tissue acid extract, anti-M2 IgG antibodies were always present in CNS tissue of chronic EAE animals, and the amount of these antibodies were related to the severity of symptoms and lesions. No antibody response to proteolipid or to galactocerebroside was detected in serum or CNS tissue. BP-immunized controls showed no chronic EAE and no response to M2 in their serum or CNS tissue. Inasmuch as M2 has been shown to be a glycoprotein of CNS myelin, and anti-M2 antibodies to have a demyelinating property, the latter would be responsible for CNS tissue demyelination in chronic EAE. A shared role of BP and M2 in the induction of chronic EAE in the guinea pig is suggested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765095     DOI: 10.1016/0896-8411(89)90149-2

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  6 in total

Review 1.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

Review 2.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.

Authors:  Patrick Peschl; Monika Bradl; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

Review 3.  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?

Authors:  Franziska Di Pauli; Thomas Berger
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

4.  Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program.

Authors:  Matteo Gastaldi; Elisabetta Zardini; Silvia Scaranzin; Antonio Uccelli; Francesca Andreetta; Fulvio Baggi; Diego Franciotta
Journal:  Front Neurol       Date:  2020-01-14       Impact factor: 4.003

5.  Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody-associated disease: a systematic review and meta-analysis.

Authors:  Qi-Lun Lai; Yin-Xi Zhang; Meng-Ting Cai; Yang Zheng; Song Qiao; Gao-Li Fang; Chun-Hong Shen
Journal:  Ther Adv Neurol Disord       Date:  2021-11-10       Impact factor: 6.570

6.  The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON.

Authors:  Yajun Yao; Xindi Li; Yun Xu; Xiaofang Liang; Liu Yang; Fu-Dong Shi; Xinghu Zhang; De-Cai Tian; Xuxiang Zhang
Journal:  BMC Neurol       Date:  2022-08-27       Impact factor: 2.903

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.